Literature DB >> 3312031

[Treatment of intra-abdominal infections with beta-lactam antibiotics. Results of some controlled prospective studies].

H R Gonzenbach1.   

Abstract

Between April, 1980 and August, 1985, 240 patients were operated on for localised or generalised intraabdominal infection and in addition received anti-microbial therapy. Thirty-one patients were treated with latamoxef, 33 with ceftazidime, 20 with ceftriaxone, 47 with imipenem/cilastatin, and 109 with a combination of aminoglycosides and clindamycin (control group). The indications for surgery included: post operative peritonitis; gall bladder empyema; perforated gastroduodenal ulcer; perforation of the small intestine with or without ileus; perforated appendicitis; perforation of the colon. On average, treatment with latamoxef amounted to 12 days, with ceftazidime: 9.4 days, with ceftriaxone 8.4 days and with imipenem/cilastatin 6.7 days. The clinical success occurred in 84% of those treated with latamoxef, 79% for ceftazidime, 50% for ceftriaxone and 81% for imipenem/cilastatin. The rate of clinical success for patients treated with an aminoglycoside/clindamycin combination was 58%. The effectiveness of the beta-lactam antibiotics studied was at least equal to that of the aminoglycoside/clindamycin combination. The beta-lactam antibiotics had the advantage of a simpler clinical application, unlike treatment with aminoglycosides, where serum level monitoring is necessary. These clinical results were not as a rule improved upon following an extension of the period of treatment by one week.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312031     DOI: 10.1007/BF01645866

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  1 in total

Review 1.  [Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy].

Authors:  K-F Bodmann
Journal:  Chirurg       Date:  2010-01       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.